Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

President Lee Nominates Competition-friendly Bureaucrat As New Health Minister

This article was originally published in PharmAsia News

Executive Summary

SEOUL - South Korea President Lee Myung-bak nominated a new minister of Health and Welfare in a partial cabinet shuffle Aug. 30, and his nominee is viewed as a market-oriented bureaucrat who could introduce foreign-friendly policies for Korea's healthcare market

You may also be interested in...



South Korea’s Health Ministry Takes Narrow View On OTC Sales, Limiting Products Like J&J’s Tylenol

After nearly two years of debate, South Korea’s health ministry will allow 13 OTC products to be sold in 24-hour convenience shops, but excludes most supermarkets.

South Korea’s Health Ministry Takes Narrow View On OTC Sales, Limiting Products Like J&J’s Tylenol

After nearly two years of debate, South Korea’s health ministry will allow 13 OTC products to be sold in 24-hour convenience shops, but excludes most supermarkets.

Korea Launches Inter-agency Body To Stimulate Local R&D, Earmarks $440 Million For Program

SEOUL - The Korean government has set up an inter-ministry team to support local pharmaceutical companies develop globally competitive drugs. The team will offer R&D training for companies looking to diversify their generic pipelines with innovative products as well as some of the start-up cash needed for new R&D programs

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

SC078956

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel